Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
37
PEN Quote, Financials, Valuation and Earnings
Last price:
$230.13
Seasonality move
:
1.03%
Day range:
$232.88 - $240.19
52-week range:
$148.00 - $310.00
Dividend yield:
0%
P/E ratio:
221.14x
P/S ratio:
7.47x
P/B ratio:
7.48x
Volume:
555.8K
Avg. volume:
430K
1-year change:
19.14%
Market cap:
$9.1B
Revenue:
$1.2B
EPS (TTM):
$1.06
Analysts' Opinion
-
Consensus RatingPenumbra has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $313.81, Penumbra has an estimated upside of 33.87% from its current price of $234.41.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $260.00 representing -10.92% downside risk from its current price of $234.41.
Fair Value
-
According to the consensus of 15 analysts, Penumbra has 33.87% upside to fair value with a price target of $313.81 per share.
PEN vs. S&P 500
-
Over the past 5 trading days, Penumbra has underperformed the S&P 500 by -4.14% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Penumbra does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Penumbra has grown year-over-year revenues for 19 quarters straight. In the most recent quarter Penumbra reported revenues of $324.1M.
Earnings Growth
-
Penumbra has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Penumbra reported earnings per share of $1.00.
Enterprise value:
8.7B
EV / Invested capital:
--
Price / LTM sales:
7.47x
EV / EBIT:
169.11x
EV / Revenue:
7.01x
PEG ratio (5yr expected):
0.06x
EV / Free cash flow:
57.86x
Price / Operating cash flow:
61.63x
Enterprise value / EBITDA:
119.76x
Gross Profit (TTM):
$789.7M
Return On Assets:
2.74%
Net Income Margin (TTM):
3.41%
Return On Equity:
3.62%
Return On Invested Capital:
3.62%
Operating Margin:
12.45%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $884.6M | $1.1B | $1.2B | $278.7M | $324.1M | |
| Gross Profit | $558.9M | $712.7M | $789.7M | $181.1M | $215.9M | |
| Operating Income | $18.1M | $95.9M | $114.5M | $12.1M | $40.4M | |
| EBITDA | $42.9M | $115.5M | $72.6M | $22.5M | $49.2M | |
| Diluted EPS | $0.16 | $2.37 | $1.06 | $0.28 | $1.00 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $635.1M | $690.3M | $786.5M | $935M | $999.7M | |
| Total Assets | $840.8M | $1.3B | $1.4B | $1.6B | $1.6B | |
| Current Liabilities | $111.9M | $130.1M | $146.3M | $152.8M | $158.6M | |
| Total Liabilities | $190.4M | $342.3M | $370.8M | $376.3M | $380.4M | |
| Total Equity | $650.5M | $959.3M | $1B | $1.2B | $1.2B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$38M | $122.5M | $179.2M | $38.3M | $49M | |
| Cash From Investing | $49.8M | -$8.4M | $58.7M | $18.4M | -$502K | |
| Cash From Financing | $15.6M | $14M | -$83.5M | -$794K | $2.7M | |
| Free Cash Flow | -$56.3M | $105.4M | $150.3M | $32.5M | $35.5M | |
PEN
Sector
Market Cap
$9.1B
$34.4M
Price % of 52-Week High
75.62%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
19.14%
-37.36%
Beta (5-Year)
0.473
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$241.56
200-day SMA
Sell
Level
$253.73
Bollinger Bands (100)
Sell
Level
254.58 - 287.66
Chaikin Money Flow
Sell
Level
-1.1M
20-day SMA
Sell
Level
$249.19
Relative Strength Index (RSI14)
Sell
Level
24.82
ADX Line
Sell
Level
35.9
Williams %R
Buy
Level
-93.9584
50-day SMA
Sell
Level
$262.86
MACD (12, 26)
Buy
Level
64.98
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Sell
Level
-2.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (15.8503)
Buy
CA Score
(Annual)
Level (1.0703)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (0.8769)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
Stock Forecast FAQ
In the current month, PEN has received 11 Buy ratings 4 Hold ratings, and 0 Sell ratings. The PEN average analyst price target in the past 3 months is $313.81.
-
Where Will Penumbra Stock Be In 1 Year?
According to analysts, the consensus estimate is that Penumbra share price will rise to $313.81 per share over the next 12 months.
-
What Do Analysts Say About Penumbra?
Analysts are divided on their view about Penumbra share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Penumbra is a Sell and believe this share price will drop from its current level to $260.00.
-
What Is Penumbra's Price Target?
The price target for Penumbra over the next 1-year time period is forecast to be $313.81 according to 15 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is PEN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Penumbra is a Buy. 11 of 15 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PEN?
You can purchase shares of Penumbra via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Penumbra shares.
-
What Is The Penumbra Share Price Today?
Penumbra was last trading at $230.13 per share. This represents the most recent stock quote for Penumbra. Yesterday, Penumbra closed at $234.41 per share.
-
How To Buy Penumbra Stock Online?
In order to purchase Penumbra stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
